AstraZeneca: Tezspire Trial Shows Reduced Polyp Size
Tezspire met primary endpoints in Phase III trial for chronic rhinosinusitis with nasal polyps, showing significant reduction in polyp size and congestion.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
